ArticleBiological procedures online2026
4-Hydroxychalcone Exert the Anti-cancer Potential in Colorectal Cancer Through Targeting CDK6.
Article in Biological procedures online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Downregulation of circ_0001112 Enhances Myocardial Infarction Through Regulation of miR-324-5p/CDK6 Axis.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a prevalent and highly lethal malignancy characterized by frequent recurrence and high mortality. 4-Hydroxychalcone (4HC), a common chalcone abundant in daily foods, exhibits multiple biomedical properties, notably anticancer activities. However, the role of 4HC in CRC remains unclear.
methodsCell proliferation was assessed using cell counting and colony formation assays. Two patient-derived organoid models of CRC and a subcutaneous xenograft model in nude mice treated with 4HC were established to evaluate tumor growth in vivo. Cell cycle distribution, intracellular reactive oxygen species (ROS), DNA damage, and cell senescence were analyzed by flow cytometry, comet assay, SA-β-Gal staining, and western blotting. Molecular docking, cellular thermal shift assay (CETSA), and surface plasmon resonance (SPR) were performed to determine the interaction between 4HC and CDK6. CDK6 expression in CRC was examined using the TCGA-COAD bulk sequencing dataset and CRC tissue microarrays via immunohistochemistry.
resultsWe systematically demonstrated that 4HC exerts anticancer effects both in vitro and in vivo. Additionally, 4HC induced cell cycle arrest, promoted ROS accumulation, and triggered DNA damage and cellular senescence in CRC cells. Mechanistically, 4HC exhibited strong binding affinity to CDK6. Furthermore, CDK6 expression was elevated in CRC tissues. Inhibition of CDK6 suppressed cell proliferation, increased ROS production, and induced senescence in CRC cells, whereas the efficacy of 4HC was significantly diminished upon CDK6 silencing.
conclusionThis study demonstrates that 4HC acts as a CDK6 inhibitor, exhibiting potent anticancer effects, and provides a potential novel therapeutic strategy for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.